{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28treatment+C%29&page=38",
    "query": {
      "intervention": "Placebo (treatment C)",
      "page": 38
    },
    "page_size": 10
  },
  "pagination": {
    "page": 38,
    "page_size": 10,
    "total_count": 988,
    "total_pages": 99,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28treatment+C%29&page=39&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28treatment+C%29&page=37&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T03:19:40.172Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05859724",
      "title": "Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "NM26-2198",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Yellow Jersey Therapeutics AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 126,
      "start_date": "2023-05-10",
      "completion_date": "2024-10-17",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-10-20T03:19:40.172Z",
      "location_count": 6,
      "location_summary": "Fountain Valley, California • Glendale, California • San Diego, California + 3 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05859724"
    },
    {
      "nct_id": "NCT00623649",
      "title": "Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HCV Infection"
      ],
      "interventions": [
        {
          "name": "VCH 916",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 42,
      "start_date": "2007-11",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2014-04-04",
      "last_synced_at": "2026-10-20T03:19:40.172Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00623649"
    },
    {
      "nct_id": "NCT04624204",
      "title": "Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab 200 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab 400 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab placebo (saline)",
          "type": "DRUG"
        },
        {
          "name": "Olaparib 300 mg BID",
          "type": "DRUG"
        },
        {
          "name": "Olaparib matching placebo",
          "type": "DRUG"
        },
        {
          "name": "Etoposide 100 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "Platinum, investigator's choice",
          "type": "DRUG"
        },
        {
          "name": "Standard Thoracic Radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "Prophylactic Cranial Irradiation (PCI)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 672,
      "start_date": "2020-12-08",
      "completion_date": "2027-11-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-20T03:19:40.172Z",
      "location_count": 35,
      "location_summary": "Chandler, Arizona • Loma Linda, California • Washington D.C., District of Columbia + 29 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04624204"
    },
    {
      "nct_id": "NCT00364104",
      "title": "Helicobacter Pylori Eradication Trial to Reduce Iron Deficiency in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Iron Deficiency"
      ],
      "interventions": [
        {
          "name": "Quadruple sequential Helicobacter pylori eradication + iron sulfate",
          "type": "DRUG"
        },
        {
          "name": "Quadruple sequential Helicobacter pylori eradication therapy",
          "type": "DRUG"
        },
        {
          "name": "Ferrous sulfate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "36 Months",
        "maximum_age": "120 Months",
        "sex": "ALL",
        "summary": "36 Months to 120 Months"
      },
      "enrollment_count": 125,
      "start_date": "2007-03",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2009-06-30",
      "last_synced_at": "2026-10-20T03:19:40.172Z",
      "location_count": 1,
      "location_summary": "El Paso, Texas",
      "locations": [
        {
          "city": "El Paso",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00364104"
    },
    {
      "nct_id": "NCT00420784",
      "title": "A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Telaprevir",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Pegylated Interferon Alfa 2a",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 465,
      "start_date": "2007-02",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2014-08-05",
      "last_synced_at": "2026-10-20T03:19:40.172Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00420784"
    },
    {
      "nct_id": "NCT05913752",
      "title": "A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Alcohol Use Disorder"
      ],
      "interventions": [
        {
          "name": "CMND-100",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clearmind Medicine Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 84,
      "start_date": "2025-04-30",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-10-20T03:19:40.172Z",
      "location_count": 2,
      "location_summary": "New Haven, Connecticut • Baltimore, Maryland",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05913752"
    },
    {
      "nct_id": "NCT01257204",
      "title": "Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C Virus"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Daclatasvir",
          "type": "DRUG"
        },
        {
          "name": "Pegylated interferon alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 196,
      "start_date": "2010-12",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2015-12-14",
      "last_synced_at": "2026-10-20T03:19:40.172Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Tulsa, Oklahoma + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01257204"
    },
    {
      "nct_id": "NCT03488147",
      "title": "Whether Proton Pump Inhibitors, Administered Prior to or After Surgery, Can Reduce the Incidence and/or Severity of Difficulty Swallowing Foods and/or Liquids,Following Anterior Cervical Surgery",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dysphagia",
        "GERD",
        "Degenerative Joint Disease"
      ],
      "interventions": [
        {
          "name": "Esomeprazole",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-07",
      "completion_date": "2020-07-02",
      "has_results": false,
      "last_update_posted_date": "2020-11-23",
      "last_synced_at": "2026-10-20T03:19:40.172Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03488147"
    },
    {
      "nct_id": "NCT07837973",
      "title": "Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Overweight , Obesity",
        "Adults"
      ],
      "interventions": [
        {
          "name": "ALV-100",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alveus Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 220,
      "start_date": "2026-08-10",
      "completion_date": "2027-08-24",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-10-20T03:19:40.172Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07837973"
    },
    {
      "nct_id": "NCT02585778",
      "title": "Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercholesterolaemia"
      ],
      "interventions": [
        {
          "name": "Alirocumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Lipid-Modifying Therapy (LMT)",
          "type": "DRUG"
        },
        {
          "name": "Antihyperglycemic Drug",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 517,
      "start_date": "2015-10-23",
      "completion_date": "2017-04-03",
      "has_results": true,
      "last_update_posted_date": "2018-05-17",
      "last_synced_at": "2026-10-20T03:19:40.172Z",
      "location_count": 29,
      "location_summary": "Encino, California • Fresno, California • Oakland, California + 25 more",
      "locations": [
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Loveland",
          "state": "Colorado"
        },
        {
          "city": "Atlantis",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02585778"
    }
  ]
}